Fibroblast growth factor 21 inhibition aggravates cardiac dysfunction in diabetic cardiomyopathy by improving lipid accumulation

Chen,Cui; Meng,Zheying; Zheng,Yuanyi; Hu,Bing; Shen,E.

doi:10.3892/etm.2017.5375

Fibroblast growth factor 21 inhibition aggravates cardiac dysfunction in diabetic cardiomyopathy by improving lipid accumulation

Authors:
- Cui Chen
- Zheying Meng
- Yuanyi Zheng
- Bing Hu
- E. Shen
View Affiliations

Affiliations: Department of Ultrasound in Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai 200233, P.R. China
Published online on: October 25, 2017 https://doi.org/10.3892/etm.2017.5375
Pages: 75-84
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Diabetic cardiomyopathy (DCM) is one of the major causes of morbidity and mortality in diabetic patients. Recent studies have demonstrated an increased level of fibroblast growth factor 21 (FGF21) in the plasma of DCM patients, and FGF21 has been proven to be a cardiovascular protector of the heart. The present study aimed to further investigate the pathogenic role of FGF21 in DCM, hypothesizing that a lack of FGF21 may promote the progression of DCM by regulating the lipid metabolism, cardiac hypertrophy and cardiac fibrosis, thus deteriorating the cardiac dysfunction. A total of 44 mice were randomly assigned into the normal (n=6), DCM (n=6), normal + scrambled siRNA (n=6), DCM + scrambled siRNA (n=6), normal + FGF21 siRNA (n=10) and DCM + FGF21 siRNA (n=10) groups. Type 1 diabetes mellitus was induced to mice in the DCM groups by streptozotocin injection, while FGF21 expression was inhibited by FGF21 siRNA. Normal and DCM mice administrated with scrambled siRNA were respectively regarded as the controls for the normal + FGF21 siRNA and DCM + FGF21 siRNA groups. In the DCM group, FGF21 inhibition promoted cardiac hypertrophy and fibrosis, and the expression levels of their indicators, including atrial natriuretic factor, α‑skeletal actin, collagen type I and III, and transforming growth factor‑β, increased, leading to further decreased cardiac function. In addition, FGF21 inhibition in DCM mice elevated the quantity of lipid droplets and the concentration of heart triglycerides, plasma triglycerides and cholesterol levels, accompanied by downregulation of peroxisome proliferator‑activated receptor γ co‑activator 1α (PGC‑1α) and upregulation of cluster of differentiation (CD)36. Thus, the results indicated that FGF21 inhibition exacerbates the cardiac dysfunction by aggravating the lipid accumulation through regulating the expression levels of PGC‑1α and CD36. In conclusion, it is suggested that FGF21 may be a potentially useful agent in the treatment of DCM.

View Figures

View References

1	Lorenzo-Almorós A, Tuñón J, Orejas M, Cortés M, Egido J and Lorenzo Ó: Diagnostic approaches for diabetic cardiomyopathy. Cardiovasc Diabetol. 16:282017. View Article : Google Scholar : PubMed/NCBI
2	Wang J, Song Y, Wang Q, Kralik PM and Epstein PN: Causes and characteristics of diabetic cardiomyopathy. Rev Diabet Stud. 3:108–117. 2006. View Article : Google Scholar : PubMed/NCBI
3	Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS and Maratos-Flier E: Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab. 5:426–437. 2007. View Article : Google Scholar : PubMed/NCBI
4	Galman C, Lundåsen T, Kharitonenkov A, Bina HA, Eriksson M, Hafström I, Dahlin M, Amark P, Angelin B and Rudling M: The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. Cell Metab. 8:169–174. 2008. View Article : Google Scholar : PubMed/NCBI
5	Cheng P, Zhang F, Yu L, Lin X, He L, Li X, Lu X, Yan X, Tan Y and Zhang C: Physiological and pharmacological roles of FGF21 in cardiovascular diseases. J Diabetes Res. 2016:15402672016. View Article : Google Scholar : PubMed/NCBI
6	Planavila A, Redondo I, Hondares E, Vinciguerra M, Munts C, Iglesias R, Gabrielli LA, Sitges M, Giralt M, van Bilsen M and Villarroya F: Fibroblast growth factor 21 protects against cardiac hypertrophy in mice. Nat Commun. 4:20192013. View Article : Google Scholar : PubMed/NCBI
7	Chow WS, Xu A, Woo YC, Tso AW, Cheung SC, Fong CH, Tse HF, Chau MT, Cheung BM and Lam KS: Serum fibroblast growth factor-21 levels are associated with carotid atherosclerosis independent of established cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 33:2454–2459. 2013. View Article : Google Scholar : PubMed/NCBI
8	Semba RD, Crasto C, Strait J, Sun K, Schaumberg DA and Ferrucci L: Elevated serum fibroblast growth factor 21 is associated with hypertension in community-dwelling adults. J Hum Hypertens. 27:397–399. 2013. View Article : Google Scholar : PubMed/NCBI
9	Lin Z, Wu Z, Yin X, Liu Y, Yan X, Lin S, Xiao J, Wang X, Feng W and Li X: Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile. PLoS One. 5:e155342010. View Article : Google Scholar : PubMed/NCBI
10	Planavila A, Redondo-Angulo I, Ribas F, Garrabou G, Casademont J, Giralt M and Villarroya F: Fibroblast growth factor 21 protects the heart from oxidative stress. Cardiovasc Res. 106:19–31. 2015. View Article : Google Scholar : PubMed/NCBI
11	Wang R, Yi X, Li X and Jiang X: Fibroblast growth factor-21 is positively associated with atrial fibrosis in atrial fibrillation patients with rheumatic heart disease. Int J Clin Exp Pathol. 8:14901–14908. 2015.PubMed/NCBI
12	Zhang W, Chu S, Ding W and Wang F: Serum level of fibroblast growth factor 21 is independently associated with acute myocardial infarction. PLoS One. 10:e01297912015. View Article : Google Scholar : PubMed/NCBI
13	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
14	Koonen DP, Glatz JF, Bonen A and Luiken JJ: Long-chain fatty acid uptake and FAT/CD36 translocation in heart and skeletal muscle. Biochim Biophys Acta. 1736:163–180. 2005. View Article : Google Scholar : PubMed/NCBI
15	Greenwalt DE, Scheck SH and Rhinehart-Jones T: Heart CD36 expression is increased in murine models of diabetes and in mice fed a high fat diet. J Clin Invest. 96:1382–1388. 1995. View Article : Google Scholar : PubMed/NCBI
16	Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW and Grishman A: New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol. 30:595–602. 1972. View Article : Google Scholar : PubMed/NCBI
17	Dandamudi S, Slusser J, Mahoney DW, Redfield MM, Rodeheffer RJ and Chen HH: The prevalence of diabetic cardiomyopathy: A population-based study in Olmsted County, Minnesota. J Card Fail. 20:304–309. 2014. View Article : Google Scholar : PubMed/NCBI
18	Yilmaz S, Canpolat U, Aydogdu S and Abboud HE: Diabetic cardiomyopathy; summary of 41 years. Korean Circ J. 45:266–272. 2015. View Article : Google Scholar : PubMed/NCBI
19	Boudina S and Abel ED: Diabetic cardiomyopathy revisited. Circulation. 115:3213–3223. 2007. View Article : Google Scholar : PubMed/NCBI
20	Muise ES, Souza S, Chi A, Tan Y, Zhao X, Liu F, Dallas-Yang Q, Wu M, Sarr T, Zhu L, et al: Downstream signaling pathways in mouse adipose tissues following acute in vivo administration of fibroblast growth factor 21. PLoS One. 8:e730112013. View Article : Google Scholar : PubMed/NCBI
21	Zhang C, Shao M, Yang H, Chen L, Yu L, Cong W, Tian H, Zhang F, Cheng P, Jin L, et al: Attenuation of hyperlipidemia- and diabetes-induced early-stage apoptosis and late-stage renal dysfunction via administration of fibroblast growth factor-21 is associated with suppression of renal inflammation. PLoS One. 8:e822752013. View Article : Google Scholar : PubMed/NCBI
22	Goldberg IJ, Trent CM and Schulze PC: Lipid metabolism and toxicity in the heart. Cell Metab. 15:805–812. 2012. View Article : Google Scholar : PubMed/NCBI
23	Neely JR, Rovetto MJ and Oram JF: Myocardial utilization of carbohydrate and lipids. Prog Cardiovasc Dis. 15:289–329. 1972. View Article : Google Scholar : PubMed/NCBI
24	Herrero P, Peterson LR, McGill JB, Matthew S, Lesniak D, Dence C and Gropler RJ: Increased myocardial fatty acid metabolism in patients with type 1 diabetes mellitus. J Am Coll Cardiol. 47:598–604. 2006. View Article : Google Scholar : PubMed/NCBI
25	Asch AS, Barnwell J, Silverstein RL and Nachman RL: Isolation of the thrombospondin membrane receptor. J Clin Invest. 79:1054–1061. 1987. View Article : Google Scholar : PubMed/NCBI
26	Silverstein RL, Asch AS and Nachman RL: Glycoprotein IV mediates thrombospondin-dependent platelet-monocyte and platelet-U937 cell adhesion. J Clin Invest. 84:546–552. 1989. View Article : Google Scholar : PubMed/NCBI
27	Endemann G, Stanton LW, Madden KS, Bryant CM, White RT and Protter AA: CD36 is a receptor for oxidized low density lipoprotein. J Biol Chem. 268:11811–11816. 1993.PubMed/NCBI
28	Koonen DP, Febbraio M, Bonnet S, Nagendran J, Young ME, Michelakis ED and Dyck JR: CD36 expression contributes to age-induced cardiomyopathy in mice. Circulation. 116:2139–2147. 2007. View Article : Google Scholar : PubMed/NCBI
29	Puigserver P, Rhee J, Donovan J, Walkey CJ, Yoon JC, Oriente F, Kitamura Y, Altomonte J, Dong H, Accili D and Spiegelman BM: Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature. 423:550–555. 2003. View Article : Google Scholar : PubMed/NCBI
30	Lin J, Handschin C and Spiegelman BM: Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab. 1:361–370. 2005. View Article : Google Scholar : PubMed/NCBI
31	Finck BN and Kelly DP: PGC-1 coactivators: Inducible regulators of energy metabolism in health and disease. J Clin Invest. 116:615–622. 2006. View Article : Google Scholar : PubMed/NCBI
32	Handschin C and Spiegelman BM: Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism. Endocr Rev. 27:728–735. 2006. View Article : Google Scholar : PubMed/NCBI
33	Potthoff MJ, Inagaki T, Satapati S, Ding X, He T, Goetz R, Mohammadi M, Finck BN, Mangelsdorf DJ, Kliewer SA and Burgess SC: FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proc Natl Acad Sci USA. 106:pp. 10853–10858. 2009; View Article : Google Scholar : PubMed/NCBI